newsfilter
← Latest News
Business Wire·

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing